Search
Insulet Corp
PODDAdd to Watchlist
140.600USD
-0.950-0.67%
Close 09-17 16:00（ET）
9.76BMarket Cap
32.63P/E TTM
More Details of Insulet Corp Company
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
Insulet Corp Profile
Ticker SymbolPODD
Company nameInsulet Corp
IPO dateMay 15, 2007
CEOMcevoy (Ashley)
Number of employees3900
Security typeOrdinary Share
Fiscal year-endMay 15
Address100 Nagog Park
CityACTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code01720-3440
Phone19786007000
Websitehttps://www.omnipod.com
Ticker SymbolPODD
IPO dateMay 15, 2007
CEOMcevoy (Ashley)
Company Executives of Insulet Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Director
Independent Director
29.36K
+5.65%
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Director
Independent Director
29.36K
+5.65%
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Director
Independent Director
29.36K
+5.65%
Mr. Michael R. Minogue
Mr. Michael R. Minogue
Independent Director
Independent Director
19.92K
+8.33%
Mr. Eric Benjamin
Mr. Eric Benjamin
Chief Operating Officer
Chief Operating Officer
16.55K
-4.75%
Mr. Eric Benjamin
Mr. Eric Benjamin
Chief Operating Officer
Chief Operating Officer
16.55K
-4.75%
Mr. Eric Benjamin
Mr. Eric Benjamin
Chief Operating Officer
Chief Operating Officer
16.55K
-4.75%
Ms. Elizabeth H. (Bess) Weatherman
Ms. Elizabeth H. (Bess) Weatherman
Independent Director
Independent Director
10.35K
+33.33%
Ms. Elizabeth H. (Bess) Weatherman
Ms. Elizabeth H. (Bess) Weatherman
Independent Director
Independent Director
10.35K
+33.33%
Ms. Elizabeth H. (Bess) Weatherman
Ms. Elizabeth H. (Bess) Weatherman
Independent Director
Independent Director
10.35K
+33.33%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Director
Independent Director
29.36K
+5.65%
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Director
Independent Director
29.36K
+5.65%
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Director
Independent Director
29.36K
+5.65%
Mr. Michael R. Minogue
Mr. Michael R. Minogue
Independent Director
Independent Director
19.92K
+8.33%
Mr. Eric Benjamin
Mr. Eric Benjamin
Chief Operating Officer
Chief Operating Officer
16.55K
-4.75%
Mr. Eric Benjamin
Mr. Eric Benjamin
Chief Operating Officer
Chief Operating Officer
16.55K
-4.75%
FAQs
Who are the top five shareholders of Insulet Corp?
The top five shareholders of Insulet Corp are: Dr. Jessica Hopfield, Ph.D.
How many institutions hold shares of Insulet Corp (PODD)?
As of 2026Q1, 1624 institutions hold shares of Insulet Corp, with a combined market value of approximately 73.18M, accounting for 105.65% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -1617450.00.
What is the biggest source of revenue for Insulet Corp?
In 2026Q1, the U.S.Omnipod business generated the highest revenue for Insulet Corp, amounting to 544.10M and accounting for 67.87% of total revenue.